Utility of 18F-FDG PET/CT for predicting pathologic complete response in hormone receptor-positive, HER2-negative breast cancer patients receiving neoadjuvant chemotherapy

Table 2 Associations between pCR and clinical/pathologic parameters from logistic regression analysis

	Variables	N	pCR	Univariate analysis			Multivariate analysis
	Variables	N	pCR	P	OR	95% CI	P	OR	95% CI
Age, years	< 50	66 (60.6)	5 (7.6)	0.817	1		0.656	1
Age, years	≥50	43 (39.4)	3 (7.0)		0.915	0.207–4.043		1.231	0.266–8.164
Menopausal status	Pre	75 (68.8)	5 (6.7)		1
Menopausal status	Post	34 (31.2)	3 (8.8)	0.690	1.355	0.305–6.027
Clinical stage	2A	10 (9.2)	0	0.997	–	–	0.890	–	–
	2B	36 (33.0)	3 (37.5)
	3A	48 (44.0)	4 (50.0)
	3B,C	15 (13.8)	1 (12.5)
Tumor size	1	8 (7.3)	0	0.996	1
	2	77 (70.6)	6 (7.8)		–	–
	3–4	24 (22)	2 (8.3)		–	–
LN involvement	0	8 (7.3)	0	0.979	1
	1	46 (42.2)	4 (8.7)		–	–
	2	45 (41.3)	3 (6.7)		–	–
	3	10 (9.2)	1 (10.0)		–	–
ER, Allred score	0–4	18 (16.5)	3 (16.7)	0.114	1
ER, Allred score	5–8	91 (83.5)	5 (5.5)		0.291	0.63–1.346
PR, Allred score	0–4	27 (24.8)	2 (25)	0.988	1
PR, Allred score	5–8	82 (75.2)	6 (75)		0.987	0.187–5.205
Ki67 index, %	< 14	54 (49.5)	2 (3.7)	0.168	1
Ki67 index, %	≥14	55 (50.5)	6 (10.9)		3.184	0.613–16.531
Molecular subtype	Luminal A-like	75 (68.8)	5 (4.2)	0.274	1		0.294	1
Molecular subtype	Luminal B-like	34 (31.2)	3 (9.8)		2.509	0.483–13.032		2.570	0.441–14.973
Regimen	AC4 or TC	4 (3.7)	1 (25.0)	0.206	1
Regimen	AC4T4	105 (96.3)	7 (6.7)		0.214	0.020–2.338
pSUVmax	< 9.55	70 (64.2)	1 (1.4)	0.013	1		0.013	1
pSUVmax	≥ 9.55	39 (35.8)	7 (17.9)		15.094	1.782–127.880		17.452	1.847–164.892

Numbers in parentheses are percentages. Abbreviations: ER Estrogen receptor; PR Progesterone receptor; pSUVmax SUVmax of primary breast tumor, CR Complete response, AC Anthracycline + cyclophosphamide, T Taxane, TC Docetaxel + cyclophosphamide, BCS Breast conserving surgery, OR Odds ratio, CI Confidence interval

ISSN: 1471-2407